NovAliX has announced that it has entered into drug discovery collaboration in the field of osteoarthritis with Galapagos.
Under the terms of this agreement NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.
NovAliX will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound-protein interactions and then further progress this program to the lead candidate stage by applying its medicinal chemistry and structural biology expertise.
NovAliX will receive technology access fees, research funding and is eligible to receive success-based milestones from Galapagos.
"We look forward to utilizing NovAliX’s capabilities in biophysics and lead generation methodologies for this novel target based drug discovery program" said Dr Graham Dixon, Senior Vice President Drug Discovery, at Galapagos.
Stephan Jenn, President of NovAliX, said: "This drug discovery collaboration with a leading European biotech confirms the quality of our technologies and science, and underlines the value of our platform as an important tool to deliver valuable lead candidates."